Trial Profile
A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2024
Price :
$35
*
At a glance
- Drugs Diphenhydramine/lorazepam/zolpidem (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Sequential Medicine Ltd
- 15 Apr 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 20 Apr 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 20 Apr 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.